{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:59:22Z","timestamp":1780779562418,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neurot.2026.e00918","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:26:17Z","timestamp":1778761577000},"page":"e00918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase 1, safety, tolerability, and pharmacokinetics study of bisnorcymserine, a highly selective inhibitor of butyrylcholinesterase"],"prefix":"10.1016","volume":"23","author":[{"given":"Iason","family":"Tzieras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Manolopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tweedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Maccecchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine M.","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Greig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kapogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neurot.2026.e00918_bib1","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Public Health"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00918_bib2","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s41467-025-56690-4","article-title":"Drug repurposing for Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"16","author":"Cummings","year":"2025","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00918_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00570","article-title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer\u2019s disease: strategies and research directions","volume":"22","author":"Cummings","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00918_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","article-title":"New approaches to symptomatic treatments for Alzheimer\u2019s disease","volume":"16","author":"Cummings","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00918_bib5","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2026.e00918_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s11357-025-02052-3","article-title":"Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia","author":"Zuliani","year":"2025","journal-title":"GeroScience"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00918_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrn1035","article-title":"Neurobiology of butyrylcholinesterase","volume":"4","author":"Darvesh","year":"2003","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00918_bib8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0306-4522(01)00613-3","article-title":"Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine","volume":"110","author":"Mesulam","year":"2002","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00918_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1185\/03007990152673800","article-title":"A new therapeutic target in Alzheimer\u2019s disease treatment: attention to butyrylcholinesterase","volume":"17","author":"Greig","year":"2001","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00918_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0197-0186(92)90189-X","article-title":"Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer\u2019s disease resemble embryonic development--a study of molecular forms","volume":"21","author":"Arendt","year":"1992","journal-title":"Neurochem Int"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00918_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2990.1978.tb00545.x","article-title":"Changes in brain cholinesterases in senile dementia of Alzheimer type","volume":"4","author":"Perry","year":"1978","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00918_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0021-5198(19)31381-2","article-title":"From molecular structure to Alzheimer therapy","volume":"74","author":"Giacobini","year":"1997","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.neurot.2026.e00918_bib13","series-title":"Physiology, acetylcholinesterase. StatPearls","author":"Trang","year":"2025"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00918_bib14","article-title":"A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer\u2019s disease","volume":"15","author":"Nordberg","year":"2013","journal-title":"Prim Care Companion CNS Disord"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00918_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/(SICI)1096-9861(19980413)393:3<374::AID-CNE8>3.0.CO;2-Z","article-title":"Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation","volume":"393","author":"Darvesh","year":"1998","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.neurot.2026.e00918_bib16","series-title":"The biology of cholinesterases","first-page":"596","author":"Silver","year":"1974"},{"key":"10.1016\/j.neurot.2026.e00918_bib17","series-title":"Medicinal Chemistry of Alzheimer\u2019s disease","first-page":"79","article-title":"Butyrylcholinesterase, the Cinderella cholinesterase, as a drug target for Alzheimer\u2019s diseases and related dementias","author":"Greig","year":"2008"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00918_bib18","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1021\/jm980459s","article-title":"Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer\u2019s disease","volume":"42","author":"Yu","year":"1999","journal-title":"J Med Chem"},{"issue":"47","key":"10.1016\/j.neurot.2026.e00918_bib19","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00918_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/JAD-2006-10108","article-title":"Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine","volume":"10","author":"Kamal","year":"2006","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00918_bib21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/j.1552-4604.1990.tb03576.x","article-title":"Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer\u2019s disease","volume":"30","author":"Puri","year":"1990","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00918_bib22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2174\/156720510791383868","article-title":"Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues","volume":"7","author":"Darvesh","year":"2010","journal-title":"Curr Alzheimer Res"},{"issue":"Suppl 2","key":"10.1016\/j.neurot.2026.e00918_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00002093-199501002-00005","article-title":"Cholinesterases and the pathology of Alzheimer disease","volume":"9","author":"Geula","year":"1995","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.neurot.2026.e00918_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111012","article-title":"Interaction of exogenous acetylcholinesterase and butyrylcholinesterase with amyloid-beta plaques in human brain tissue","volume":"395","author":"Reid","year":"2024","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00918_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2225797","article-title":"A method for the efficient evaluation of substrate-based cholinesterase imaging probes for Alzheimer\u2019s disease","volume":"38","author":"Darvesh","year":"2023","journal-title":"J Enzym Inhib Med Chem"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00918_bib26","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/jnnp-2012-302589","article-title":"Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-beta peptide and tau levels: target engagement, tolerability and pharmacokinetics in humans","volume":"83","author":"Maccecchini","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00918_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/biom14050582","article-title":"Comparative analysis of posiphen pharmacokinetics across different species-similar absorption and metabolism in Mouse, Rat, dog and human","volume":"14","author":"Maccecchini","year":"2024","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00918_bib28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1567205054367829","article-title":"An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease","volume":"2","author":"Greig","year":"2005","journal-title":"Curr Alzheimer Res"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:22:53Z","timestamp":1780777373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1878747926000887"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00918","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1, safety, tolerability, and pharmacokinetics study of bisnorcymserine, a highly selective inhibitor of butyrylcholinesterase","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00918"}}